Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28055725 | 0.86 | TAAR1 (0.45) | TAAR1SLC6A2SLC6A3AOC3KCNH2 | |
| SCHEMBL432651 | 0.74 | TAAR1 (0.50) | TAAR1SLC6A2SLC6A3AOC3KCNH2 | |
| SCHEMBL8471773 | 0.72 | TAAR1 (0.52) | TAAR1AOC3KCNH2MAOBIDO1 | |
| SCHEMBL9112609 | 0.71 | KCNH2 (0.49) | TAAR1SLC6A2SLC6A3AOC3KCNH2 | |
| SCHEMBL9150371 | 0.71 | TAAR1 (0.47) | TAAR1SLC6A2SLC6A3AOC3KCNH2 | |
| SCHEMBL4902643 | 0.70 | TAAR1 (0.50) | TAAR1AOC3KCNH2MAOBIDO1 | |
| SCHEMBL896217 | 0.70 | TAAR1 (0.50) | TAAR1AOC3KCNH2MAOBIDO1 | |
| SCHEMBL27912646 | 0.70 | TAAR1 (0.56) | TAAR1SLC6A2SLC6A3AOC3KCNH2 | |
| SCHEMBL436099 | 0.70 | AOC3 (0.52) | TAAR1SLC6A2SLC6A3AOC3KCNH2 | |
| SCHEMBL2135113 | 0.69 | TAAR1 (0.68) | TAAR1AOC3MAOBIDO1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802845-B2 | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto | Arena Phamaceuticals, Inc. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130178619-A1 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2013-07-11 | — | — | US | disclosed |
| US-8168782-B2 | synthesis of lorcaserin | ARENA PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | ARENA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178619-A1 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | HTR2C, HTR3C, HTR1A | TAAR1 203/4885SLC6A2 136/4885SLC6A3 59/4885 |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | HTR2C, HTR3C, HTR1A | TAAR1 203/4885SLC6A2 136/4885SLC6A3 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.